Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. …
Over the last 12 months, insiders at Schrödinger, Inc. have bought $0 and sold $216,981 worth of Schrödinger, Inc. stock.
On average, over the past 5 years, insiders at Schrödinger, Inc. have bought $14.31M and sold $348.21M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,115 shares for transaction amount of $111,386 was made by Lebowitz Joel (EVP & CFO) on 2021‑02‑05.
2024-10-15 | Sale | Chief Medical Officer | 1,531 0.002% | $17.78 | $27,226 | +1.53% | ||
2024-03-04 | Sale | EVP & CFO | 3,315 0.0048% | $26.35 | $87,360 | -13.90% | ||
2024-02-12 | Sale | EVP, CTO & COO, Software | 901 0.0013% | $28.29 | $25,489 | -21.96% | ||
2024-02-12 | Sale | EVP, CLO & CPO | 758 0.0011% | $28.29 | $21,444 | -21.96% | ||
2024-02-12 | Sale | SVP & Controller | 787 0.0011% | $28.29 | $22,264 | -21.96% | ||
2024-02-12 | Sale | See Remarks | 1,205 0.0016% | $27.55 | $33,198 | -21.96% | ||
2023-08-09 | Sale | EVP & Chief Technology Officer | 10,000 0.0141% | $40.06 | $400,642 | -32.63% | ||
2023-06-30 | Sale | EVP, CLO & CPO | 12,040 0.0169% | $50.00 | $602,000 | -44.89% | ||
2023-05-23 | Sale | EVP & Chief Technology Officer | 10,000 0.0146% | $40.06 | $400,587 | -21.63% | ||
2023-05-23 | Sale | EVP, CLO & CPO | 7,960 0.0116% | $40.01 | $318,461 | -21.63% | ||
2023-05-22 | Sale | EVP, CLO & CPO | 15,000 0.0189% | $35.04 | $525,632 | -22.16% | ||
2023-05-22 | Sale | director | 14,850 0.0187% | $35.00 | $519,750 | -22.16% | ||
2023-02-02 | Sale | EVP & Chief Legal Officer | 25,000 0.0345% | $27.26 | $681,380 | +8.38% | ||
2023-01-04 | Sale | President & CEO | 66,886 0.0939% | $18.28 | $1.22M | +62.24% | ||
2022-08-11 | Sale | 4,950 0.0078% | $35.00 | $173,250 | -16.27% | |||
2021-12-13 | Sale | See Remarks | 15,601 0.0218% | $36.28 | $565,985 | -24.80% | ||
2021-10-15 | Sale | See Remarks | 1,393 0.002% | $55.75 | $77,660 | -46.13% | ||
2021-09-15 | Sale | See Remarks | 1,394 0.002% | $61.13 | $85,215 | -48.42% | ||
2021-09-13 | Sale | See Remarks | 15,602 0.0218% | $61.75 | $963,435 | -49.57% | ||
2021-09-02 | Sale | EVP & CFO | 3,874 0.0055% | $64.62 | $250,353 | -50.90% |
BILL & MELINDA GATES FOUNDATION TRUST | 10 percent owner | 6981664 9.5907% | $18.86 | 1 | 3 | +110.06% |
Flynn James E | 10 percent owner | 250000 0.3434% | $18.86 | 1 | 0 | +110.06% |
Lebowitz Joel | EVP & CFO | 0 0% | $18.86 | 1 | 13 | <0.0001% |
BlackRock | $248.22M | 12.65 | 9.19M | +4.91% | +$11.61M | 0.01 | |
Bill Melinda Gates Foundation Trust | $188.5M | 9.61 | 6.98M | 0% | +$0 | 0.41 | |
The Vanguard Group | $183.84M | 9.37 | 6.81M | +0.48% | +$874,611.00 | <0.01 | |
Baillie Gifford Co | $70.52M | 3.59 | 2.61M | +0.37% | +$259,686.00 | 0.06 | |
ARK Investment Management LLC | $67.99M | 3.47 | 2.52M | -17.54% | -$14.46M | 0.24 |